Det foreslås, at patienter, der formodes at have reduceret reaktion på behandlingen, overvåges regelmæssigt for dannelse af IgG antistoffer over for imiglucerase.
It is suggested that patients suspected of a decreased response to the treatment be monitored periodically for IgG antibody formation to imiglucerase.